FBIOP.PFD (Fortress Biotech) Short Percentage of Float

View and export this data going back to 2017. Start your Free Trial

What is Fortress Biotech Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Fortress Biotech's Short Percentage of Float

For the Biotechnology subindustry, Fortress Biotech's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortress Biotech's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Short Percentage of Float falls into.

Fortress Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIOP.PFD) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

FBIO:USA CNB0.PFD:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154

Website

https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.